desvenlafaxine succinate sustained-release

DRUG2 trials

Sponsors

Pfizer

Conditions

Major Depressive Disorder

Phase 3

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

CompletedNCT01371734

PfizerMajor Depressive Disorder

Start: 2011-08-31End: 2015-09-30Updated: 2017-03-20

Phase 4

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

CompletedNCT01121484

PfizerMajor Depressive Disorder

Start: 2010-06-30End: 2011-06-30Updated: 2012-04-04

Related Papers

Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials

Journal of Clinical Psychopharmacology2021-06-291 citations

Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.

2016-01-133 citations

A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d

The Primary Care Companion For CNS Disorders2015-06-0411 citations

Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis.

2015-03-267 citations

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

The Journal of Clinical Psychiatry2013-10-1589 citations